Skip to main content

Metabolic Risk Contributes to Diabetes Onset in People With HIV

Medically reviewed by Carmen Pope, BPharm. Last updated on Oct 8, 2024.

By Elana Gotkine HealthDay Reporter

MONDAY, Oct. 7, 2024 -- For people with HIV (PWH) with low-to-moderate atherosclerotic cardiovascular disease (ASCVD) risk, metabolic risk factors contribute to new-onset diabetes mellitus (DM) among those treated with pitavastatin or placebo, according to a study published online Oct. 8 in the Annals of Internal Medicine.

Kathleen V. Fitch, from Massachusetts General Hospital and Harvard Medical School in Boston, and colleagues examined the contribution of known DM risk factors to excess risk for DM with pitavastatin use among PWH in the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) trial. Participants included 7,731 PWH aged 40 to 75 years with a low-to-moderate risk for ASCVD, without DM at study entry, who were randomly assigned to pitavastatin 4 mg daily or placebo in a 1:1 ratio.

The researchers found that in each treatment group, participants with at least three DM risk factors versus no risk factors had an increased risk for DM (incidence rate, 3.24 versus 0.34 per 100 person-years in the pitavastatin group and 2.66 versus 0.27 per 100 person-years in the placebo group). The highest incidence of DM was seen in South Asia. High body mass index, prediabetes, and metabolic syndrome components were strongly associated with new-onset DM in adjusted analyses.

"Together these data suggest the importance of implementing comprehensive risk reduction strategies for PWH with risk factors for DM, including dietary and exercise interventions," the authors write.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted October 2024

Read this next

Urinary Incontinence Linked to CVD Risk Factors, Comorbid Conditions

FRIDAY, May 2, 2025 -- Urinary incontinence is not associated with moderate-to-vigorous physical activity (MVPA) classification, but is associated with cardiovascular disease...

Many Medicaid Enrollees Have Restricted Access to SGLT2 Inhibitors, GLP-1 Receptor Agonists

WEDNESDAY, April 30, 2025 -- Many Medicaid enrollees with type 2 diabetes have restricted access to cardioprotective medications, including sodium-glucose cotransporter-2...

Sodium-Glucose Cotransporter 2 Inhibitors Increase Risk for Falls in Patients With Diabetes

WEDNESDAY, April 30, 2025 -- Sodium-glucose cotransporter 2 (SGLT2) inhibitor use is an independent risk factor for falls in people with type 2 diabetes, according to a study...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.